Johnson & Johnson advances IBD therapy, despite trial miss The drugmaker plans to focus on a subgroup of patients in late-stage testing By Allison DeAngelisMay 5, 2026 Biotech Startups and Venture Capital Reporter

https://www.statnews.com/2026/05/05/johnson-and-johnson-ibd-therapy-no-meaningful-improvement/